Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +0.67%68 ROA % is 15.89% as of Mar. 2026, which is 12% below its 10-year median of 17.98. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,665.32 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, Concord Biotech ranks better than 93.14% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Concord Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹3,552 Mil.
Concord Biotech's average Total Assets over the quarter that ended in Mar. 2026 was ₹22,347 Mil. Therefore, Concord Biotech's annualized ROA % for the quarter that ended in Mar. 2026 was 15.89%.
The historical rank and industry rank for Concord Biotech's ROA % or its related term are showing as below:
BOM:543960'
s ROA % Range Over the Past 10 Years
Min: 12.22 Med: 17.98 Max: 22.13
Current: 12.37
During the past 7 years, Concord Biotech's highest ROA % was 22.13%. The lowest was 12.22%. And the median was 17.98%.
BOM:543960's ROA % is ranked better than 93.14% of 1413
companies
in the Biotechnology industry
Industry Median: -32.84
vs BOM:543960: 12.37
Concord Biotech (BOM:543960) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Concord Biotech ROA % Related Terms
Concord Biotech ROA % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Concord Biotech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's ROA % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Concord Biotech (BOM:543960) has a ROA % of 15.89% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Concord Biotech and its competitors. This is 12% below median its historical median of 17.98. Over the past decade, Concord Biotech's ROA % has ranged from 12.22 to 22.13. According to the industry distribution chart, Concord Biotech ranks #97 out of 1413 companies in the Biotechnology industry, placing it in the top 6.9%.
Is Concord Biotech's ROA % too high?
Concord Biotech's current ROA % of 15.89% is 12% below median its 10-year median of 17.98. Over the past 10 years, this metric has ranged from a low of 12.22 to a high of 22.13. Based on the distribution chart, Concord Biotech ranks #97 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #97 out of 1413 companies for ROA %. This places Concord Biotech in the top 7% of its industry — outperforming the majority of peers. Historically, Concord Biotech's own ROA % has ranged from 12.22 to 22.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Concord Biotech and its competitors. Concord Biotech's current ROA % is 15.89%, which is 12% below median its own 10-year median of 17.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,665.32, compared to a current price of ₹1,257.00 — trading 24.5% below its estimated fair value. The current ROA % is 15.89%, which is 12% below median its 10-year median of 17.98. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current ROA % is 15.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.5% below its estimated GF Value™ of ₹1,665.32.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
ROA %: 15.89% (12% below median its 10-year median of 17.98)
GF Value™: ₹1,665.32 vs. price of ₹1,257.00 (24.5% below fair value)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
